Close
Human factors is not simply a labeling or documentation exercise. For medical device manufacturers, human factors and usability engineering are fundamental parts of designing a device that intended users can operate safely and effectively within its intended use environment.
A strong medical device human factors strategy considers how real users interact with a device, the environment in which the device will be used, the tasks users are expected to perform, and the potential consequences of use errors. These considerations should be addressed throughout development rather than being introduced only when a marketing submission is being prepared.
For medical device sponsors, this means considering questions such as:
Who are the intended users of the device?
In what environments will the device be used?
Which user interactions could affect safety or effectiveness?
What are the device’s critical tasks?
What potential use errors could occur?
How have those risks been reduced through design or other controls?
What evidence demonstrates that representative users can operate the device safely and effectively?
These questions are closely connected to broader medical device risk management, clinical development, evidence planning, and FDA submission readiness. Human factors considerations should therefore remain aligned with the proposed intended use, indications for use, target users, use environment, device design, risk-management strategy, clinical evidence, labeling, and regulatory submission pathway.
FDA further clarified its expectations for human factors information in medical device submissions in 2026.
In May 2026, FDA issued its final guidance, Content of Human Factors Information in Medical Device Marketing Submissions. The guidance provides a risk-based framework for determining what human factors information should be documented and submitted to FDA based on the potential for use-related risks associated with a device. The guidance applies across major medical device marketing pathways, including 510(k) premarket notifications, De Novo classification requests, Premarket Approval (PMA) applications, and Humanitarian Device Exemption (HDE) applications.
The practical implication for sponsors is significant. FDA human factors expectations are not simply about providing a usability report at the end of development. Sponsors need to demonstrate that the device’s intended users, intended use, use environments, critical tasks, user interface, use-related risks, and risk controls have been considered systematically throughout the development process. FDA subsequently updated its broader Applying Human Factors and Usability Engineering to Medical Devices guidance in August 2026, further reinforcing the importance of incorporating usability engineering into the medical device development lifecycle.
Together, the 2026 FDA human factors guidance documents reinforce a clear principle: human factors should be integrated into medical device development from the beginning, not treated as a final submission activity. Waiting until late-stage submission preparation to address human factors can expose inconsistencies between device design, risk documentation, clinical evidence, and the way the product is expected to be used in practice.
A stronger development approach therefore treats FDA human factors requirements as part of the overall medical device development and evidence strategy, helping sponsors build a more coherent, traceable, and submission-ready regulatory package.
Medical device design should begin with a realistic understanding of who will actually interact with the product. Depending on the device, intended users may include physicians, nurses, technicians, caregivers, patients or other healthcare personnel.
Different users may have different levels of training, physical capability, experience and familiarity with the technology.
FDA’s human factors framework considers three interconnected elements: users, use environments and the device user interface. Those elements should be considered early because they affect both usability and potential use-related risks.
A device used in a controlled hospital environment may encounter very different conditions from one used at home, in an ambulance, laboratory, physician office or decentralized care setting.
Lighting, noise, interruptions, physical space, connectivity, protective equipment and time pressure can all change how users interact with a device.
Human factors validation therefore needs to represent the intended users and use environment, rather than evaluate the interface in an unrealistic setting.
One of the most important development activities is identifying critical tasks. These are tasks where a use error, failure to complete the task or incorrect performance could affect safety or effectiveness.
Examples may include configuring a device, interpreting a result, selecting parameters, administering treatment, responding to an alarm or completing an essential maintenance step.
Sponsors should identify these tasks through the use-related risk-analysis process and evaluate whether the user interface creates avoidable opportunities for error.
Human factors should not operate separately from device risk management.
FDA’s 2026 human factors guidance emphasizes using usability engineering to identify and reduce use-related risks.
Where applicable, sponsors should ensure consistency between: intended use → users → use environment → critical tasks → use-related risks → risk controls → validation evidence.
Risk documentation should also remain aligned with the product’s broader risk-management framework, including applicable ISO 14971 principles.
Human factors validation should not be the first time sponsors discover that users struggle with an interface.
Formative evaluations provide an opportunity to identify usability issues while the design can still be improved.
Sponsors may use formative work to evaluate instructions, controls, displays, alarms, workflows, packaging and other user-interface elements.
The objective is not merely to prove that the current design works. It is to improve the design before final validation.
Once the interface has matured, validation should demonstrate that the device can be used safely and effectively by representative intended users under conditions that appropriately reflect the intended use environment.
Validation should be tied directly to the risk analysis and critical tasks.
Sponsors should therefore be able to explain:
That connection between risk, design and evidence becomes important when FDA reviews the submission.
FDA’s May 2026 guidance uses a risk-based framework for determining the level of human factors information to include in marketing submissions.
The documentation should not be treated as an isolated usability report. It should clearly show how the sponsor assessed use-related risks, designed appropriate controls and generated evidence supporting safe and effective use.
Importantly, FDA updated both IVD and non-IVD eSTAR templates in 2026 to incorporate content from the new Human Factors Content Guidance. That makes early alignment even more important.
The strongest programs do not ask: “What human factors document does FDA need?”
They ask: “How should we design this device so intended users can use it safely and effectively?”
The documentation then becomes evidence of that development process. That is a much stronger position than trying to generate a regulatory narrative after product design is largely complete.
Dynamill Research supports medical-device sponsors by connecting regulatory strategy, clinical development, evidence planning, risk management, human factors considerations, and FDA submission readiness within one coordinated development approach. For programs involving human factors and usability engineering, this means looking beyond the final validation study. Human factors requirements should remain connected to the broader medical-device development strategy from the beginning, including the proposed intended use, indications for use, target users, use environment, device interface, clinical evidence, and known or foreseeable risks.
Dynamill can help sponsors evaluate whether these elements remain aligned as the program progresses. For example, the intended users and intended use environment identified during development should be consistent with the population, workflows, and operating conditions represented in the supporting clinical and usability evidence.
Our approach can include supporting teams with:
Intended use and user-profile alignment to ensure that the proposed use of the device is clearly reflected across clinical, human factors, and regulatory documentation.
Human factors evidence planning to help determine where formative evaluations, usability assessments, and validation activities fit within the broader development roadmap.
Use-related risk considerations so that critical tasks, potential use errors, risk controls, and supporting evidence remain connected to the overall device risk-management process.
Clinical evidence strategy to ensure that clinical-development activities support the device claims, target population, and intended-use conditions being presented to FDA.
Evidence-gap assessment to identify areas where additional clinical, usability, risk-management, or regulatory evidence may be needed before submission.
FDA interaction planning, including preparation for appropriate Q-Submission or Pre-Submission discussions when sponsor questions could materially affect the development approach.
Submission-readiness review to help ensure that human factors information, clinical evidence, risk documentation, labeling, and other supporting materials tell a consistent regulatory story.
For medical-device programs, one of the most important objectives is traceability across development activities. Sponsors should be able to demonstrate how the intended use and device design connect with identified risks, human factors activities, clinical evidence, and the final claims presented in the marketing submission.
A strong development pathway should therefore show a logical progression such as:
Intended Use → Intended Users & Use Environment → Use-Related Risks → Risk Controls → Human Factors Evidence → Clinical Evidence → Submission
When these components are developed separately, inconsistencies may only become visible late in the process. Addressing them earlier can help reduce avoidable rework, strengthen the evidence package, and improve overall FDA submission readiness. Dynamill’s role is to help sponsors maintain this alignment throughout development rather than treating human factors, clinical evidence, and regulatory documentation as separate workstreams. By connecting human factors strategy with clinical development and FDA regulatory planning, Dynamill helps medical-device sponsors move toward submission with a clearer evidence story, fewer unresolved gaps, and a more coherent and defensible development package.